Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

How do tumor cells respond to HDAC inhibition?

27 Apr 2016

Abstract excerpt

It is now well recognized that mutations, deregulated expression, and aberrant recruitment of epigenetic readers, writers, and erasers are fundamentally important processes in the onset and maintenance of many human tumors. The molecular, biological, and biochemical characteristics of a particular class of epigenetic erasers, the histone deacetylases (HDACs), have been extensively studied and small-molecule HDAC...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Histone Deacetylase Inhibitors Research
Share to Peptidase Inhibition and Analysis
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27112360
DOI: 10.1111/febs.13746

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

How do tumor cells respond to HDAC inhibition?PMID 27112360Read ↗

Advances of HDAC inhibitors in tumor therapy: potential applications through immune modulationSemantic proximity Read ↗

HDAC Inhibitors as Epigenetic Regulators of the Immune System: Impacts on Cancer Therapy and Inflammatory DiseasesSemantic proximity Read ↗

Role of HDACs in normal and malignant hematopoiesisSemantic proximity Read ↗

HDAC inhibitors and immunotherapy; a double edged sword?Semantic proximity Read ↗

Histone deacetylases as therapeutic targets in hematologic malignanciesSemantic proximity Read ↗

Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes.Semantic proximity Read ↗

Histone Deacetylase Inhibitors as Immunomodulators in Cancer TherapeuticsSemantic proximity Read ↗

Inhibition of histone deacetylases in cancer therapy: lessons from leukaemiaSemantic proximity Read ↗

The epigenetic revolution in hematology: from benchside breakthroughs to clinical transformationsSemantic proximity Read ↗

Epigenetic Modifiers in Myeloid Malignancies: The Role of Histone Deacetylase InhibitorsSemantic proximity Read ↗

Mechanisms of Histone Deacetylase Inhibitor-Regulated Gene Expression in Cancer CellsSemantic proximity Read ↗

HDAC inhibitors in cancer biology: emerging mechanisms and clinical applicationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.